Home » Stocks » TAK

Takeda Pharmaceutical Company Limited (TAK)

Stock Price: $16.71 USD -0.04 (-0.24%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $16.72 +0.01 (0.06%) Feb 26, 7:59 PM
Market Cap 53.07B
Revenue (ttm) 30.50B
Net Income (ttm) 410.02M
Shares Out 1.68B
EPS (ttm) 0.81
PE Ratio 20.59
Forward PE 8.76
Dividend $1.64
Dividend Yield 9.78%
Trading Day February 26
Last Price $16.71
Previous Close $16.75
Change ($) -0.04
Change (%) -0.24%
Day's Open 16.81
Day's Range 16.57 - 16.96
Day's Volume 4,779,218
52-Week Range 11.82 - 19.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 2 days ago

Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: ANTM, BHC, DD, NSC, THC
Benzinga - 2 days ago

Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1...

Business Wire - 2 days ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing ...

Business Wire - 4 days ago

MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.

Benzinga - 4 days ago

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical tria...

Other stocks mentioned: NVAX
Business Wire - 4 days ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of No...

Zacks Investment Research - 1 week ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Business Wire - 1 week ago

ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient ...

Benzinga - 2 weeks ago

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has announced data from SOLSTICE Phase 3 trial, evaluating maribavir (TAK-620) in hematopoietic cell transplant and solid organ transplant recipients w...

Business Wire - 2 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint

Benzinga - 2 weeks ago

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with n...

Business Wire - 2 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Lab...

Business Wire - 3 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended ...

Business Wire - 3 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Business Wire - 3 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Seal...

Business Wire - 4 weeks ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pro...

Business Wire - 1 month ago

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-78...

Business Wire - 1 month ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 20...

Business Wire - 1 month ago

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicin...

Seeking Alpha - 1 month ago

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT, HASI, HMHC, LXRX, MNKD, NKTR, NNOX, OBSV, PSNL, PTY, ROAD, SGRY, SP, UTF, XRM
Business Wire - 1 month ago

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top...

PRNewsWire - 1 month ago

EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured nota...

Other stocks mentioned: SPEX
GuruFocus - 1 month ago

According to the Aggregated Portfolio of Gurus, a Premium feature of GuruFocus, the Hennessy Japan Fund (Trades, Portfolio), the T. Rowe Price Japan Fund (Trades, Portfolio) and the Matthews J...

Other stocks mentioned: DKILY, FRCOY, SFTBY
Business Wire - 1 month ago

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on the progress of its continued transformation and gr...

InvestorPlace - 1 month ago

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

Other stocks mentioned: ABBV, BMY, JNJ, NVS, PFE, SNY
Business Wire - 1 month ago

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Confer...

GuruFocus - 1 month ago

Screening the market for securities whose market capitalization surpasses $2 billion and whose price-book ratios are trading below 1.5 could yield a higher likelihood of unearthing value oppor...

Other stocks mentioned: EPRT, NOK
Business Wire - 1 month ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pre...

Business Wire - 2 months ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core pres...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the su...

Business Wire - 2 months ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepte...

Reuters - 2 months ago

Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.

Business Wire - 2 months ago

OSAKA, Japan--(BUSINESS WIRE)--As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline p...

Business Wire - 2 months ago

SHANGHAI & OSAKA, Japan--(BUSINESS WIRE)--Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

Business Wire - 2 months ago

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting.

Business Wire - 2 months ago

CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antih...

Business Wire - 2 months ago

INCHEON, South Korea--(BUSINESS WIRE)-- #Acquisition--Celltrion completed an acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited.

Business Wire - 2 months ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select pro...

PRNewsWire - 2 months ago

THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB)...

Other stocks mentioned: AMGN
Business Wire - 3 months ago

PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tre...

Bloomberg Markets and Finance - 3 months ago

Takeda Pharma's Venkayya on Global Race for Covid Vaccines

Nov.22 -- Rajeev Venkayya, president of the global vaccine business unit of Japan's Takeda Pharmaceutical Co., discusses the latest developments in the global race for Covid-19 vaccines. The c...

The Motley Fool - 3 months ago

The numbers are close, but two players stand out at the moment.

Other stocks mentioned: AZN, BNTX, MRNA, NVAX, PFE
Business Wire - 3 months ago

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced it will present nine company-sponsored abstracts at the 62nd Americ...

Reuters - 3 months ago

Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber ...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at th...

Seeking Alpha - 3 months ago

Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Seqster PDM Inc. ("Seqster") the award winning healthcare technology company and Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda")...

Business Wire - 3 months ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended Septe...

Business Wire - 3 months ago

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine cand...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan.

Other stocks mentioned: MRNA

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1781
CEO
Christophe Weber
Employees
47,495
Stock Exchange
NYSE
Ticker Symbol
TAK
Full Company Profile

Financial Performance

In 2019, TAK's revenue was 3.29 trillion, an increase of 56.93% compared to the previous year's 2.10 trillion. Earnings were 44.24 billion, a decrease of -67.28%.

Financial numbers in millions JPY.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 22.74, which is an increase of 36.09% from the latest price.

Price Target
$22.74
(36.09% upside)
Analyst Consensus: Buy